Resistance to adefovir dipivoxil in lamivudine resistant chronic hepatitis B patients treated with adefovir dipivoxil

BACKGROUND: Adefovir dipivoxil (ADV) is a potent nucleotide analogue against both the wild‐type and lamivudine (LMV) resistant hepatitis B virus (HBV). The cumulative incidence of ADV resistant mutations in the nucleoside/‐tide treatment naïve chronic hepatitis B patient (CHB) at weeks 48, 96, and 1...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Yeon, J E, Yoo, W, Hong, S P, Chang, Y J, Yu, S K, Kim, J H, Seo, Y S, Chung, H J, Moon, M S, Kim, S‐O, Byun, K S, Lee, C H
Formato: Artigo
Idioma:Inglês
Publicado em: BMJ Group 2006
Assuntos:
Hepatitis
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC1856440/
https://ncbi.nlm.nih.gov/pubmed/16461777
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/gut.2005.077099
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados